<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="32898">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02678377</url>
  </required_header>
  <id_info>
    <org_study_id>STU00201249</org_study_id>
    <nct_id>NCT02678377</nct_id>
  </id_info>
  <brief_title>The SLIM Study: Sling and Botox® Injection for Mixed Urinary Incontinence</brief_title>
  <official_title>The SLIM Study: Sling and Botox® Injection for Mixed Urinary Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Friends of Prentice Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This double-blind randomized controlled trial seeks to find a better treatment for women
      with mixed urinary incontinence (both stress and urgency incontinence). The primary aim is
      to determine whether midurethral sling surgery combined with injections of
      onabotulinumtoxinA (Botox®) into the detrusor muscle of the bladder improves symptoms of
      mixed urinary incontinence better than sling surgery alone.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Self-reported mixed urinary incontinence symptoms</measure>
    <time_frame>3 months after surgery</time_frame>
    <description>Mixed urinary incontinence symptoms will be assessed by the Patient Global Assessment of Improvement (PGI-I) survey, a patient oriented outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incontinence episode frequency</measure>
    <time_frame>3 months after surgery</time_frame>
    <description>Incontinence episode frequency will be assessed by a self-report 3-day urinary diary completed by the subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary incontinence symptoms and quality of life</measure>
    <time_frame>3 months after surgery</time_frame>
    <description>Urinary incontinence symptoms and quality of life will be assessed by a satisfaction survey completed by the subject</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Mixed Urinary Incontinence</condition>
  <condition>Stress Urinary Incontinence</condition>
  <condition>Urgency Incontinence</condition>
  <arm_group>
    <arm_group_label>OnabotulinumtoxinA injections</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 units of OnabotulinumtoxinA (Botox®) injected into the detrusor (large muscle of the bladder) at the time of sling surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline injections</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>100 units of saline injected into the detrusor (large muscle of the bladder) at the time of sling surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OnabotulinumtoxinA (Botox ®) Injections</intervention_name>
    <description>OnabotulinumtoxinA (Botox ®) is a neurotoxin, which inhibits acetylcholine release and temporarily relaxes the bladder muscle to inhibit urgency incontinence.</description>
    <arm_group_label>OnabotulinumtoxinA injections</arm_group_label>
    <other_name>Botox ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Injections</intervention_name>
    <description>Saline will be injected into the bladder so that investigators are masked to subject randomization.</description>
    <arm_group_label>Saline injections</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Undergoing mid-urethral sling surgery

          -  Have symptoms of both stress and urgency urinary incontinence

          -  Able to consent, fill out study documents, and complete all study procedures and
             follow-up visits

          -  At least 18 years of age

          -  English speaking

          -  Be able and willing to learn clean intermittent self catheterization technique

        Exclusion Criteria:

          -  History of recurrent UTI (defined as three culture proven UTIs within last 12 months)

          -  Systemic neuromuscular disease known to affect the lower urinary tract

          -  Undergoing concomitant prolapse surgery

          -  Previous incontinence surgery

          -  Treatment with anticholinergic medication in the last 2 months

          -  Previous bladder injection with onabotulinumtoxinA

          -  Prisoner Status

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimberly Kenton, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor, Departments of Obstetrics and Gynecology, Urology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alix Leader-Cramer, M.D.</last_name>
    <phone>312-472-3874</phone>
    <email>aleaderc@nm.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexis Siurek, B.S.</last_name>
    <phone>312-695-7748</phone>
    <email>alexis.siurek@nm.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Northwestern Medicine Integrated Pelvic Health Clinic</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexis Siurek</last_name>
      <phone>312-695-7748</phone>
      <email>alexis.siurek@nm.org</email>
    </contact>
    <contact_backup>
      <last_name>Alix Leader-Cramer, MD</last_name>
      <phone>312-472-3874</phone>
      <email>aleaderc@nm.org</email>
    </contact_backup>
    <investigator>
      <last_name>Kimberly Kenton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 28, 2017</lastchanged_date>
  <firstreceived_date>February 5, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Kimberly Kenton</investigator_full_name>
    <investigator_title>Professor, Departments of Obstetrics and Gynecology, Urology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>incobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
